今日の臨床サポート 今日の臨床サポート
関連論文:
img  2:  Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy.
 
著者: Jay D Raman, Casey K Ng, Douglas S Scherr, Vitaly Margulis, Yair Lotan, Karim Bensalah, Jean-Jacques Patard, Eiji Kikuchi, Francesco Montorsi, Richard Zigeuner, Alon Weizer, Christian Bolenz, Theresa M Koppie, Hendrik Isbarn, Claudio Jeldres, Wareef Kabbani, Mesut Remzi, Mathias Waldert, Christopher G Wood, Marco Roscigno, Mototsuga Oya, Cord Langner, J Stuart Wolf, Philipp Ströbel, Mario Fernández, Pierre Karakiewcz, Shahrokh F Shariat
雑誌名: Eur Urol. 2010 Jun;57(6):1072-9. doi: 10.1016/j.eururo.2009.07.002. Epub 2009 Jul 15.
Abstract/Text BACKGROUND: There is a lack of consensus regarding the prognostic significance of ureteral versus renal pelvic upper tract urothelial carcinoma (UTUC).
OBJECTIVE: To investigate the association of tumor location on outcomes for UTUC in an international cohort of patients managed by radical nephroureterectomy (RNU).
DESIGN, SETTING, AND PARTICIPANTS: A retrospective review of institutional databases from 10 institutions worldwide identified patients with UTUC.
INTERVENTION: The 1249 patients in the study underwent RNU with ipsilateral bladder cuff resection between 1987 and 2007.
MEASUREMENTS: Data accrued included age, gender, race, surgical approach (open vs laparoscopic), tumor pathology (stage, grade, lymph node status), tumor location, use of perioperative chemotherapy, prior endoscopic therapy, urothelial carcinoma recurrence, and mortality from urothelial carcinoma. Tumor location was divided into two groups (renal pelvis and ureter) based on the location of the dominant tumor.
RESULTS AND LIMITATIONS: The 5-yr recurrence-free and cancer-specific survival estimates for this cohort were 75% and 78%, respectively. On multivariate analysis, only pathologic tumor (pT) classification (p<0.001), grade (p<0.02), and lymph node status (p<0.001) were associated with disease recurrence and cancer-specific survival. When adjusting for these variables, there was no difference in the probability of disease recurrence (hazard ratio [HR]: 1.22; p=0.133) or cancer death (HR: 1.23; p=0.25) between ureteral and renal pelvic tumors. Adding tumor location to a base prognostic model for disease recurrence and cancer death that included pT stage, tumor grade, and lymph node status only improved the predictive accuracy of this model by 0.1%. This study is limited by biases associated with its retrospective design.
CONCLUSIONS: There is no difference in outcomes between patients with renal pelvic tumors and with ureteral tumors following nephroureterectomy. These data support the current TNM staging system, whereby renal pelvic and ureteral carcinomas are classified as one integral group of tumors.

Copyright © 2009 European Association of Urology. Published by Elsevier B.V. All rights reserved.
PMID 19619934  Eur Urol. 2010 Jun;57(6):1072-9. doi: 10.1016/j.eururo.2009.07.002. Epub 2009 Jul 15.
戻る

さらなるご利用にはご登録が必要です。

こちらよりご契約または優待日間無料トライアルお申込みをお願いします。

(※トライアルご登録は1名様につき、一度となります)


ご契約の場合はご招待された方だけのご優待特典があります。

以下の優待コードを入力いただくと、

契約期間が通常12ヵ月のところ、14ヵ月ご利用いただけます。

優待コード: (利用期限:まで)

ご契約はこちらから